This is a phase 4 open-label study aiming to explore the relationship between clinical response to erenumab and genetic biomarkers.~Subjects with episodic or chronic migraine will be treated with Erenumab 70mg or 140mg for a 4-week baseline/screening period, followed by a 24-week treatment period.~Subjects will collect migraine-related parameters daily using an eDiary and blood samples will be collected for biomarker research. All analysis will be descriptive in nature.
To explore the relationship between clinical response to erenumab and genetic biomarkers